Third-line Treatment of mRCC
No data is available. If the patient is physically fi t to receive further treatment, there can be a discussion regarding the pros and cons of using a targeted therapy in the above list that has not been used before.
Recommendations for Third-line Treatment of mRCC
It was unanimously decided (100%) that the Canadian guideline can be adapted (Supplementary Table 1). In addition, the group agreed that it should be made clear to patients of the lack of data guiding treatment in third-line. Similar to that of first- and second-line, best supportive care will be listed as an option for third-line (Table 1)